Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Proceedings of the National Academy of Sciences · 08.10.2024 · 121 (41)
DOI: 10.1073/pnas.2408469121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 30.09.2024. Verfasst von Imrul Shahriar und 6 weiteren Autor:innen. Beteiligte Einrichtung: James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907. Hauptthemen laut MEDLINE: Orthomyxoviridae Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907.
- Eradivir Inc., West Lafayette, IN 47906.
- Department of Biological Sciences, Purdue University, West Lafayette, IN 47907.
ORCID-Profile: Imrul Shahriar, Mohini Kamra, Ananda Kumar Kanduluru, Thanh Hiep Nguyen, Philip S Low
Zitieren
APA
Shahriar, I., Kamra, M., Kanduluru, A. K., Campbell, C. L., Nguyen, T. H., Srinivasarao, M., & Low, P. S. (2024). Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections. Proceedings of the National Academy of Sciences, 121(41). https://doi.org/10.1073/pnas.2408469121
Vancouver
Shahriar I, Kamra M, Kanduluru AK, Campbell CL, Nguyen TH, Srinivasarao M, et al. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections. Proceedings of the National Academy of Sciences. 2024;121(41). doi:10.1073/pnas.2408469121
BibTeX
@article{Shahriar2024,
author = {Shahriar, Imrul and Kamra, Mohini and Kanduluru, Ananda Kumar and Campbell, Charity Lynn and Nguyen, Thanh Hiep and Srinivasarao, Madduri and Low, Philip S},
title = {Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {41},
doi = {10.1073/pnas.2408469121}
}
EUVIMED